📰 9 sources covering this story

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

First covered 1 days ago · latest take 20 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

STAT News1 days ago

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.

The trial being halted comes as another blow to the pharmaceutical company

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review WSJ

The Times1 days ago

AstraZeneca posts two wins and a setback for lung cancer pipeline The Times

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

Reuters🏁 first to report1 days ago

AstraZeneca to discontinue late-stage lung cancer trial for volrustomig Reuters